Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
SARS-CoV-2 Breakthrough Infections after Introduction of 4 COVID-19 Vaccines, South Korea, 2021
- Authors
- Yi, Seonju; Choe, Young June; Kim, Jia; Kim, Yoo-Yeon; Kim, Ryu Kyung; Jang, Eun Jung; Lim, Do Sang; Byeon, Hye Ryeon; Lee, Sangwon; Park, Eonjoo; Kim, Seung-Jin; Park, Young-Joon
- Issue Date
- 3월-2022
- Publisher
- CENTERS DISEASE CONTROL & PREVENTION
- Citation
- EMERGING INFECTIOUS DISEASES, v.28, no.3, pp.753 - 756
- Indexed
- SCIE
SCOPUS
- Journal Title
- EMERGING INFECTIOUS DISEASES
- Volume
- 28
- Number
- 3
- Start Page
- 753
- End Page
- 756
- ISSN
- 1080-6040
- Abstract
- We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.